Not provided
Not provided
Not provided
Not provided
Not provided
Unable to obtain Myeliviz for trial
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Case Western Reserve University | OTHER |
Not provided
Not provided
Not provided
This study evaluates the safety of [11C]MeDAS, a PET radiotracer.
Myelin PET imaging provides a new type of information regarding the integrity of the central nervous system based on molecular imaging of myelin. Preclinical studies have shown [11C] MeDAS uptake in the brain and spinal cord to be an indicator of the microstructural integrity of the tissue.
[11C]MeDAS PET (Positron Emission Tomography) scans will be performed on healthy subjects at 2 timepoints to assess for safety of the radiotracer and to assess its performance in humans. Following measurement of [11C]MeDAS pharmacokinetics and biodistribution, an optimal protocol for dosing and imaging will be established.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Arm: Healthy subjects | Experimental | The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time. This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [11C]MeDAS | Drug | PET radiotracer |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Radiation dosimetry | Whole body radiotracer uptake, as measured using PET scan image data. Radiotracer uptake will be measured in absolute counts and using distribution volume ratios. | Less than or equal to 2 hours |
| Biodistribution analysis | Organ-specific radiotracer uptake, as measured using PET scan image data. Radiotracer uptake will be measured in absolute counts and using distribution volume ratios. | Less than or equal to 2 hours |
| Metabolism analysis | Analysis of in vivo radiotracer metabolism using liquid chromatography, with quantification of relative peak areas under the curve. | Less than or equal to 2 hours |
| Pharmacokinetic analysis based on PET scan data | Determination of time-dependent radiotracer distribution using PET scan image data, with time measurement in minutes, PET data measured in absolute counts, and position in the body determined by organ segmentation. | Less than or equal to 2 hours |
| Analysis of time-dependent radiotracer distribution based on arterial blood sampling | Determination of time-dependent radiotracer distribution as assessed by arterial blood sampling, using scintillation counting for determination of radiotracer activity. Time is measured in minutes and radiotracer quantity is assayed by scintillation counting with units in absolute counts. | Less than or equal to 2 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Brain imaging characterization | Analyze patterns of radiotracer distribution in the brain using PET scan image data. This is an intrinsically qualitative analysis and image data will be assessed by visual inspection. Based on findings of this first-in-human study, preliminary quantitative assessment using coregistration with structural imaging, anatomic segmentation and partial volume correction will be performed to calculate distribution volume ratios for areas of interest. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Fox, MD | The Cleveland Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
data will be available per NIH policies
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003711 | Demyelinating Diseases |
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000594970 | N-methyl-4,4'-diaminostilbene |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Less than or equal to 2 hours |
| Spinal cord imaging characterization | Analyze patterns of radiotracer distribution in the spinal cord using PET scan image data. This is an intrinsically qualitative analysis and image data will be assessed by visual inspection. Based on findings of this first-in-human study, preliminary quantitative assessment using coregistration with structural imaging, anatomic segmentation and partial volume correction will be performed to calculate distribution volume ratios for areas of interest. | Less than or equal to 2 hours |